MicroRNA-29 fine-tunes the expression of key foxa2- Activated lipid metabolism genes and is dysregulated in animal models of insulin resistance and diabetes

Diabetes

Volumn 63, Issue 9, 2014, Pages 3141-3148

  Kurtz, C Lisa ^a   Peck, Bailey C E ^b   Fannin, Emily E ^c   Beysen, Carine ^c   Miao, Ji ^d   Landstreet, Stuart R ^e   Ding, Shengli ^f   Turaga, Vandana ^a   Lund, P Kay ^f   Turner, Scott ^c   Biddinger, Sudha B ^d   Vickers, Kasey C ^e   Sethupathy, Praveen ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c KINEMED INC   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 3BETA; MESSENGER RNA; MICRORNA 29; PIOGLITAZONE;

ABHD5 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GENE; GENE EXPRESSION; HEPATOMA CELL; HMGCS2 GENE; HOMEOSTASIS; HUMAN; HUMAN CELL; INSULIN RESISTANCE; LIPID METABOLISM; MOUSE; NONHUMAN; PPARGC1A GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SEQUENCE ANALYSIS; UPREGULATION; ZUCKER DIABETIC FATTY RAT;

ANIMALS; CELL LINE, TUMOR; DIABETES MELLITUS, TYPE 2; FEMALE; HEPATOCYTE NUCLEAR FACTOR 3-BETA; HUMANS; INSULIN RESISTANCE; MICE; MICRORNAS; MODELS, ANIMAL; RATS; RATS, ZUCKER; THIAZOLIDINEDIONES; UP-REGULATION;

EID: 84906657316     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-1015     Document Type: Article

References (53)

1. Kadowaki T. Insights into insulin resistance and type 2 diabetes from knockout mouse models. J Clin Invest 2000;106:459-465
2. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215-233
3. Kim W, Kyung Lee E. Post-transcriptional regulation in metabolic diseases. RNA Biol 2012;9:772-780
4. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105: 10513-10518
5. Karolina DS, Tavintharan S, Armugam A, et al. Circulating miRNA profiles in patients with metabolic syndrome. J Clin Endocrinol Metab 2012;97:E2271-E2276
6. Couzin J. MicroRNAs make big impression in disease after disease. Science 2008;319:1782-1784
7. van Rooij E, Purcell AL, Levin AA. Developing microRNA therapeutics. Circ Res 2012;110:496-5078
8. Jackson AL, Levin AA. Developing microRNA therapeutics: Approaching the unique complexities. Nucleic Acid Ther 2012;22:213-225
9. Fernandez-Valverde SL, Taft RJ, Mattick JS. MicroRNAs in b-cell biology, insulin resistance, diabetes and its complications. Diabetes 2011;60:1825-1831
10. Quiat D, Olson EN. MicroRNAs in cardiovascular disease: from pathogenesis to prevention and treatment. J Clin Invest 2013;123:11-18
11. Williams MD, Mitchell GM. MicroRNAs in insulin resistance and obesity. Exp Diabetes Res 2012;2012:484696
12. Vickers KC, Shoucri BM, Levin MG, et al. MicroRNA-27b is a regulatory hub in lipid metabolism and is altered in dyslipidemia. Hepatology 2013;57:533-542
13. Rayner KJ, Suárez Y, Dávalos A, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010;328:1570-1573
14. Najafi-Shoushtari SH, Kristo F, Li Y, et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010;328:1566-1569
15. Marquart TJ, Allen RM, Ory DS, Baldán A. miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci U S A 2010;107:12228-12232
16. Horie T, Ono K, Horiguchi M, et al. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci U S A 2010;107:17321-17326
17. Rayner KJ, Sheedy FJ, Esau CC, et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 2011;121:2921-2931
18. Rayner KJ, Esau CC, Hussain FN, et al. Inhibition of miR-33a/b in nonhuman primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011; 478:404-407
19. Dávalos A, Goedeke L, Smibert P, et al. miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci U S A 2011;108:9232-9237
20. Kornfeld JW, Baitzel C, Könner AC, et al. Obesity-induced overexpression of miR-802 impairs glucose metabolism through silencing of Hnf1b. Nature 2013; 494:111-115
21. Trajkovski M, Hausser J, Soutschek J, et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 2011;474:649-653
22. Kole AJ, Swahari V, Hammond SM, Deshmukh M. miR-29b is activated during neuronal maturation and targets BH3-only genes to restrict apoptosis. Genes Dev 2011;25:125-130
23. van Rooij E, Sutherland LB, Thatcher JE, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 2008;105:13027-13032
24. Han YC, Park CY, Bhagat G, et al. microRNA-29a induces aberrant selfrenewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia. J Exp Med 2010;207:475-489
25. Martinez I, Cazalla D, Almstead LL, Steitz JA, DiMaio D. miR-29 and miR-30 regulate B-Myb expression during cellular senescence. Proc Natl Acad Sci U S A 2011;108:522-527
26. Ma F, Xu S, Liu X, et al. The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-γ. Nat Immunol 2011;12:861-869
27. Baran-Gale J, Fannin EE, Kurtz CL, Sethupathy P. Beta cell 59-shifted isomiRs are candidate regulatory hubs in type 2 diabetes. PLoS One 2013;8: e73240
28. Bagge A, Clausen TR, Larsen S, et al. MicroRNA-29a is up-regulated in beta-cells by glucose and decreases glucose-stimulated insulin secretion. Biochem Biophys Res Commun 2012;426:266-272
29. Pullen TJ, da Silva Xavier G, Kelsey G, Rutter GA. miR-29a and miR-29b contribute to pancreatic beta-cell-specific silencing of monocarboxylate transporter 1 (Mct1). Mol Cell Biol 2011;31:3182-3194
30. Hoffman BG, Robertson G, Zavaglia B, et al. Locus co-occupancy, nucleosome positioning, and H3K4me1 regulate the functionality of FOXA2-, HNF4A-, and PDX1-bound loci in islets and liver. Genome Res 2010;20:1037-1051
31. Sethupathy P. Illuminating microRNA Transcription from the Epigenome. Curr Genomics 2013;14:68-77
32. Yokoi N, Hoshino M, Hidaka S, et al. A novel rat model of type 2 diabetes: the Zucker fatty diabetes mellitus ZFDM rat. J Diabetes Res 2013;2013:103731
33. Wolfrum C, Besser D, Luca E, Stoffel M. Insulin regulates the activity of forkhead transcription factor Hnf-3beta/Foxa-2 by Akt-mediated phosphorylation and nuclear/cytosolic localization. Proc Natl Acad Sci U S A 2003;100:11624-11629
34. Yoon JC, Puigserver P, Chen G, et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 2001;413:131-138
35. Puigserver P, Rodgers JT. Foxa2, a novel transcriptional regulator of insulin sensitivity. Nat Med 2006;12:38-39
36. Wolfrum C, Stoffel M. Coactivation of Foxa2 through Pgc-1beta promotes liver fatty acid oxidation and triglyceride/VLDL secretion. Cell Metab 2006;3:99-110
37. Osella M, Bosia C, Corá D, Caselle M. The role of incoherent microRNAmediated feedforward loops in noise buffering. PLOS Comput Biol 2011;7: e1001101
38. Lord CC, Betters JL, Ivanova PT, et al. CGI-58/ABHD5-derived signaling lipids regulate systemic inflammation and insulin action. Diabetes 2012;61:355-363
39. Vilà-Brau A, De Sousa-Coelho AL, Mayordomo C, Haro D, Marrero PF. Human HMGCS2 regulates mitochondrial fatty acid oxidation and FGF21 expression in HepG2 cell line. J Biol Chem 2011;286:20423-20430
40. Pandey AK, Verma G, Vig S, Srivastava S, Srivastava AK, Datta M. miR-29a levels are elevated in the db/db mice liver and its overexpression leads to attenuation of insulin action on PEPCK gene expression in HepG2 cells. Mol Cell Endocrinol 2011;332:125-133
41. Zampetaki A, Kiechl S, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010;107:810-817
42. Kong L, Zhu J, Han W, et al. Significance of serum microRNAs in prediabetes and newly diagnosed type 2 diabetes: A clinical study. Acta Diabetol 2011;48:61-69
43. Boon RA, Vickers KC. Intercellular transport of microRNAs. Arterioscler Thromb Vasc Biol 2013;33:186-192
44. Vickers KC, Remaley AT. Lipid-based carriers of microRNAs and intercellular communication. Curr Opin Lipidol 2012;23:91-97
45. Turchinovich A, Samatov TR, Tonevitsky AG, Burwinkel B. Circulating miRNAs: cell-cell communication function? Front Genet 2013;4:119
46. Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 2011;108:5003-5008
47. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res 2012;110: 483-495
48. Montecalvo A, Larregina AT, Shufesky WJ, et al. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood 2012; 119:756-766
49. Mittelbrunn M, Gutierrez-Vazquez C, Villarroya-Beltri C, et al. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat Comm 2011;2:282
50. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by highdensity lipoproteins. Nat Cell Biol 2011;13:423-433
51. van de Bunt M, Gaulton KJ, Parts L, et al. The miRNA profile of human pancreatic islets and beta-cells and relationship to type 2 diabetes pathogenesis. PLoS One 2013;8:e55272
52. Tsang J, Zhu J, van Oudenaarden A. MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals. Mol Cell 2007;26: 753-767
53. Siciliano V, Garzilli I, Fracassi C, Criscuolo S, Ventre S, di Bernardo D. MiRNAs confer phenotypic robustness to gene networks by suppressing biological noise. Nat Comm 2013;4:2364